Skip to main content

26.03.2024 | Editorial Commentary

Advancing equitable access to care and optimal medication practice. World Kidney Day 2024

verfasst von: Florencio A. McCarthy, Melvin Bonilla-Felix

Erschienen in: Pediatric Nephrology

Einloggen, um Zugang zu erhalten

Excerpt

The International Society of Nephrology (ISN) and the International Federation of Kidney Foundations (IFKF) have sponsored a joint initiative to celebrate, the second Thursday of March, the global campaign of World Kidney Day, which has the following objectives: the promotion of systematic screening of patients at risk of chronic kidney disease, the dissemination of preventive strategies, the education of health personnel and governors in their role to detect and prevent chronic kidney disease, and the promotion of kidney transplantation as the best treatment option especially in children. The committee has declared 2024 as the year of “Kidney Health for All” and invites us to make efforts to promote equitable access to care and the best practice of medicine. …
Literatur
1.
Zurück zum Zitat Webster AC, Nagler EV, Morton RL, Masson P (2017) Chronic kidney disease. Lancet 389:1238–1252CrossRefPubMed Webster AC, Nagler EV, Morton RL, Masson P (2017) Chronic kidney disease. Lancet 389:1238–1252CrossRefPubMed
2.
Zurück zum Zitat Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW (2013) Chronic kidney disease: global dimension and perspectives. Lancet 382:260–272CrossRefPubMed Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW (2013) Chronic kidney disease: global dimension and perspectives. Lancet 382:260–272CrossRefPubMed
3.
Zurück zum Zitat Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C (2019) A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int 96:1048–1050CrossRefPubMed Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C (2019) A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int 96:1048–1050CrossRefPubMed
4.
Zurück zum Zitat Harambat J, van Stralen KJ, Kim JJ, Tizard EJ (2012) Epidemiology of chronic kidney disease in children. Pediatr Nephrol 27:363–373CrossRefPubMed Harambat J, van Stralen KJ, Kim JJ, Tizard EJ (2012) Epidemiology of chronic kidney disease in children. Pediatr Nephrol 27:363–373CrossRefPubMed
5.
Zurück zum Zitat Harada R, Hamasaki Y, Okuda Y, Hamada R, Ishikura K (2022) Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies. Pediatr Nephrol 37:1215–1229CrossRefPubMed Harada R, Hamasaki Y, Okuda Y, Hamada R, Ishikura K (2022) Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies. Pediatr Nephrol 37:1215–1229CrossRefPubMed
6.
Zurück zum Zitat Assadi F (2013) Psychological impact of chronic kidney disease among children and adolescents: not rare and not benign. J Nephropathology 2:1–3CrossRefPubMedPubMedCentral Assadi F (2013) Psychological impact of chronic kidney disease among children and adolescents: not rare and not benign. J Nephropathology 2:1–3CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Dryjańska N, Kiliś-Pstrusińska K (2023) Depression in children and adolescents with chronic kidney disease-review of available literature. J Clin Med 12:3554CrossRefPubMedPubMedCentral Dryjańska N, Kiliś-Pstrusińska K (2023) Depression in children and adolescents with chronic kidney disease-review of available literature. J Clin Med 12:3554CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Rees L, Schaefer F, Schmitt CP, Shroff R, Warady BA (2017) Chronic dialysis in children and adolescents: challenges and outcomes. Lancet Child Adolesc Health 1:68–77CrossRefPubMed Rees L, Schaefer F, Schmitt CP, Shroff R, Warady BA (2017) Chronic dialysis in children and adolescents: challenges and outcomes. Lancet Child Adolesc Health 1:68–77CrossRefPubMed
9.
Zurück zum Zitat Harambat J, Bonthuis M, Groothoff JW, Schaefer F, Tizard EJ, Verrina E, van Stralen KJ, Jager KJ (2016) Lessons learned from the ESPN/ERA-EDTA registry. Pediatr Nephrol 31:2055–2064CrossRefPubMed Harambat J, Bonthuis M, Groothoff JW, Schaefer F, Tizard EJ, Verrina E, van Stralen KJ, Jager KJ (2016) Lessons learned from the ESPN/ERA-EDTA registry. Pediatr Nephrol 31:2055–2064CrossRefPubMed
10.
Zurück zum Zitat Pavlyatenko AS, Arsanova RA, Saakyan GR et al (2023) Renal diseases: ensuring equal access to healthcare services for all. Revista Latinoamericana de Hipertensión 18:500–506 Pavlyatenko AS, Arsanova RA, Saakyan GR et al (2023) Renal diseases: ensuring equal access to healthcare services for all. Revista Latinoamericana de Hipertensión 18:500–506
12.
Zurück zum Zitat Krissberg JR, Sutherland SM, Chamberlain LJ, Wise PH (2021) Policy in pediatric nephrology: successes, failures, and the impact on disparities. Pediatr Nephrol 36:2177–2188CrossRefPubMed Krissberg JR, Sutherland SM, Chamberlain LJ, Wise PH (2021) Policy in pediatric nephrology: successes, failures, and the impact on disparities. Pediatr Nephrol 36:2177–2188CrossRefPubMed
13.
Zurück zum Zitat Lalji R, Francis A, Johnson DW, McCulloch M (2020) Health disparities in access to kidney replacement therapy amongst children and adolescents with end-stage kidney disease in low- and lower-middle-income countries. Kidney Int 97:463–465CrossRefPubMed Lalji R, Francis A, Johnson DW, McCulloch M (2020) Health disparities in access to kidney replacement therapy amongst children and adolescents with end-stage kidney disease in low- and lower-middle-income countries. Kidney Int 97:463–465CrossRefPubMed
14.
Zurück zum Zitat Lalji R, Francis A, Wong G, Viecelli AK, Tong A, Teixeira-Pinto A, McCulloch M, Bello AK, Levin A, Lunney M, Osman MA, Ye F, Jha V, Feehally J, Harris DC, Johnson DW (2020) Disparities in end-stage kidney disease care for children: a global survey. Kidney Int 98:527–532CrossRefPubMed Lalji R, Francis A, Wong G, Viecelli AK, Tong A, Teixeira-Pinto A, McCulloch M, Bello AK, Levin A, Lunney M, Osman MA, Ye F, Jha V, Feehally J, Harris DC, Johnson DW (2020) Disparities in end-stage kidney disease care for children: a global survey. Kidney Int 98:527–532CrossRefPubMed
15.
Zurück zum Zitat Banerjee S, Kamath N, Antwi S, Bonilla-Felix M (2022) Paediatric nephrology in under-resourced areas. Pediatr Nephrol 37:959–972CrossRefPubMed Banerjee S, Kamath N, Antwi S, Bonilla-Felix M (2022) Paediatric nephrology in under-resourced areas. Pediatr Nephrol 37:959–972CrossRefPubMed
16.
Zurück zum Zitat Patzer RE, Amaral S, Klein M, Kutner N, Perryman JP, Gazmararian JA, McClellan WM (2012) Racial disparities in pediatric access to kidney transplantation: does socioeconomic status play a role? Am J Transplant 12:369–378CrossRefPubMedPubMedCentral Patzer RE, Amaral S, Klein M, Kutner N, Perryman JP, Gazmararian JA, McClellan WM (2012) Racial disparities in pediatric access to kidney transplantation: does socioeconomic status play a role? Am J Transplant 12:369–378CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Wilder ME, Kulie P, Jensen C, Levett P, Blanchard J, Dominguez LW, Portela M, Srivastava A, Li Y, McCarthy ML (2021) The impact of social determinants of health on medication adherence: a systematic review and meta-analysis. J Gen Intern Med 36:1359–1370CrossRefPubMedPubMedCentral Wilder ME, Kulie P, Jensen C, Levett P, Blanchard J, Dominguez LW, Portela M, Srivastava A, Li Y, McCarthy ML (2021) The impact of social determinants of health on medication adherence: a systematic review and meta-analysis. J Gen Intern Med 36:1359–1370CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Yinusa A, Faezipour M, Faezipour M (2022) A study on CKD progression and health disparities using system dynamics modeling. Healthcare (Basel) 10:1628CrossRefPubMed Yinusa A, Faezipour M, Faezipour M (2022) A study on CKD progression and health disparities using system dynamics modeling. Healthcare (Basel) 10:1628CrossRefPubMed
19.
Zurück zum Zitat Van Biesen W, Jha V, Abu-Alfa AK, Andreoli SP, Ashuntantang G, Bernieh B, Brown E, Chen Y, Coppo R, Couchoud C, Cullis B, Douthat W, Eke FU, Hemmelgarn B, Hou FF, Levin NW, Luyckx VA, Morton RL, Moosa MR, Murtagh FEM, Richards M, Rondeau E, Schneditz D, Shah KD, Tesar V, Yeates K, Garcia Garcia G (2020) Considerations on equity in management of end-stage kidney disease in low- and middle-income countries. Kidney Int Suppl 10:e63–e71CrossRef Van Biesen W, Jha V, Abu-Alfa AK, Andreoli SP, Ashuntantang G, Bernieh B, Brown E, Chen Y, Coppo R, Couchoud C, Cullis B, Douthat W, Eke FU, Hemmelgarn B, Hou FF, Levin NW, Luyckx VA, Morton RL, Moosa MR, Murtagh FEM, Richards M, Rondeau E, Schneditz D, Shah KD, Tesar V, Yeates K, Garcia Garcia G (2020) Considerations on equity in management of end-stage kidney disease in low- and middle-income countries. Kidney Int Suppl 10:e63–e71CrossRef
20.
Zurück zum Zitat Beran D, Pedersen HB, Robertson J (2019) Noncommunicable diseases, access to essential medicines and universal health coverage. Glob Health Action 12:1670014CrossRefPubMedPubMedCentral Beran D, Pedersen HB, Robertson J (2019) Noncommunicable diseases, access to essential medicines and universal health coverage. Glob Health Action 12:1670014CrossRefPubMedPubMedCentral
Metadaten
Titel
Advancing equitable access to care and optimal medication practice. World Kidney Day 2024
verfasst von
Florencio A. McCarthy
Melvin Bonilla-Felix
Publikationsdatum
26.03.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-024-06353-1

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.